<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143034">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053584</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0002</org_study_id>
    <nct_id>NCT02053584</nct_id>
  </id_info>
  <brief_title>Dario™ Blood Glucose Monitoring System - User Performance Evaluation</brief_title>
  <official_title>Dario™ Blood Glucose Monitoring System - User Performance Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LabStyle Innovations Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LabStyle Innovations Ltd.</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is performed to evaluate the accuracy of blood glucose level results obtained from
      fingertip using Labstyle Dario Blood Glucose Monitoring System (BGMS) compared to reference
      equipment (YSI 2300 STATPLUS) and to evaluate the ease of use of the Dario Device by the
      lay-person.

      The participants will review the Dario user manual and guide and will be requested to
      operate the Dario BGMS and perform their own glucose blood test, after which they will be
      asked to complete a questionnaire. As reference the participants will be tested by
      professional caregivers both using the Dario BGMS and by YSI 2003.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device accuracy will be assessed based on the acceptance criteria of ISO 15197:2003 which
      states: &quot;The minimum acceptable accuracy for results produced by a glucose monitoring system
      shall be as follows: 95% of the individual glucose results shall fall within 15 mg/dL of the
      results of Reference method at glucose  concentrations ≥ 4,2 mmol/L (≥ 75 mg/dL)&quot;.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Accuracy of blood glucose level measurements</measure>
    <time_frame>Within 6 seconds of applying blood drop to strip</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the ease of use of the Dario BGMS by the lay-person</measure>
    <time_frame>Within a couple of hours from the time labeling material was provided to the subject</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Dario BGMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dario™ Blood Glucose Meter</intervention_name>
    <description>Each subject will undergo a finger prick and also provide a venous blood sample</description>
    <arm_group_label>Dario BGMS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>YSI2003</intervention_name>
    <description>Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.</description>
    <arm_group_label>Dario BGMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between the age 18 and 80

          -  Type 1 and Type 2 diabetes

        Exclusion Criteria:

          -  Drug and alcohol abuse

          -  Investigator discretion
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Vainstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 31, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
